Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
24 April 2025 | Story Martinette Brits | Photo Barend Nagel
Mainstream Final Project
Five postgraduate students from Ethiopia and Togo with Prof Corli Witthuhn, coordinator of the MAINSTREAM project, during their academic exchange visit to the University of the Free State. From the left: Prudence Bilabina, Ame Houngo, Prof Corli Witthuhn, Gemedo Shengu, Fanny Sibabi, and Debela Bedada.

The University of the Free State (UFS) has welcomed a cohort of international students as part of the Mobility 4 Agricultural International Networks Supporting Thematic Resilience and Enhancing Adaptation and Mitigation (MAINSTREAM) project, a significant European Union-funded initiative aimed at boosting agricultural education and research across the African continent.

A group of postgraduate students from Togo and Ethiopia have recently joined the University of the Free State as part of the MAINSTREAM project. “Two doctoral students from Togo – Ame Houngo and Fanny Sibabi – are based in the Department of Sustainable Food Systems and Development and will be supervised by Dr Alba du Toit and Prof Maryke Labuschagne,” says Prof Corli Witthuhn from the Department of Sustainable Food Systems and Development at the UFS, who serves as the coordinator of the MAINSTREAM project. Master’s student Prudence Bilabina, also from Togo, is hosted by the Department of Agricultural Economics under the supervision of Prof Henry Jordaan.

From Ethiopia, doctoral student Debela Bedada and master’s student Gemedo Shengu are both pursuing their research in the Department of Agricultural Economics, supervised by Prof Nicky Matthews and Dr Janus Henning respectively.

A Ugandan student will soon join them on 22 April for a three-month traineeship. “He is an undergraduate Agriculture student who will register for a service-learning module at the UFS and spend the three months working on a farm,” explains Prof Witthuhn. The student hails from the Mountains of the Moon University in Uganda.

By June 2025, the university anticipates the arrival of four more students from Uganda – three at master’s level and one traineeship participant – bringing the total number of MAINSTREAM students hosted by UFS this year to ten.

 

Building a climate-resilient future through agricultural education

The MAINSTREAM project aims to foster education and skills improvement in agricultural knowledge systems, with a strong focus on climate change resilience. According to Prof Witthuhn, the project “strives to influence the common agenda for addressing education and skills improvement … targeting transformations with the tertiary agricultural education community, policy, and industry actors”.

An important aspect of the initiative is its emphasis on inclusion, particularly regarding African women who remain underrepresented in higher education agricultural programmes. “Mobility schemes will also be used to break cross-African gendered perceptions of agriculture … and to further provide for a gender-sensitive learning environment and institutional culture,” Prof Witthuhn notes.

The UFS’ participation forms part of a larger network of partner institutions across Africa and Europe, including Arsi University (Ethiopia), the University of Kara (Togo), the Mountains of the Moon University (Uganda), Jaramogi Oginga Odinga University of Science and Technology (JOOUST, Kenya), the University of Sine Saloum El Hadji Ibrahima Niasse (USSEIN, Senegal), and the Weihenstephan-Triesdorf University of Applied Science (Germany).

 

Strengthening research, networks, and collaboration at the UFS

This four-year project, running from 2024 to 2027, will host two cohorts of students. “We are a partner in the project that will run over four years … one of the UFS master’s students, Rinus Behrens from the Department of Sustainable Food Systems and Development, is currently spending four months at JOOUST in Kenya as part of the programme,” adds Prof Witthuhn.

The presence of these students at the UFS marks a pivotal moment for both the institution and its international counterparts. “For the institution, it creates the opportunity for new networks, new research opportunities, internationalisation of our research endeavour, and increased research outputs,” she says.

During their stay, master’s and doctoral students will engage in academic research aligned with their fields of study, while traineeship students will gain hands-on agricultural experience on farms in the Bloemfontein area.

Bedada says the programme is already making a meaningful impact on his academic journey. “I am analysing the impact of agricultural mechanisation on food security and production. It is a big opportunity, because it gives me a chance to expand my knowledge and skills, and to develop my research work to international level.”

Similarly, Houngo says the experience so far has been enriching. “I have already learned a lot, and I hope to replicate the experience in my hometown,” he shares.

Behind the scenes, UFS staff and departments are instrumental in ensuring the programme’s success. “They provide host departments, academic leadership, and supervision to the six students,” says Prof Witthuhn, emphasising the collaborative effort required to support this international initiative.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept